TET1

tet methylcytosine dioxygenase 1

Explore in graph →CI-GENE-00034920HGNC:29484 ENSG00000138336 NCBI 80312 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TET1 mutation1
Immune Checkpoint Inhibitor	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	3	submitted	EID12409 In a retrospective study on TCGA data, the presence of non-synonymous mutations in TET1 is enriched in patients responding to immune checkpoint inhibitor treatment (n=519, P = 0.003). In an ICI-treate… (full text at CIViC) PMID 31623662 · Wu et al., 2019 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (131)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved131 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (MSK, Clin Cancer Res 2023) bladder_msk_2023	unmapped	Ssm	15	440

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.